HER2-Low Breast Cancer: Current Landscape and Future Prospects

被引：29

作者：

Shirman, Yelena ^{[1
]}

Lubovsky, Shlomit ^{[1
]}

Shai, Ayelet ^{[1
,2
]}

机构：

[1] Rambam Hlth Care Campus, Div Oncol, Haifa, Israel

[2] Rambam Hlth Care Campus, Div Oncol, HaAliya HaShniya St 8,POB 9602, IL-3109601 Haifa, Israel

来源：

BREAST CANCER-TARGETS AND THERAPY | 2023年 / 15卷

关键词：

HER2-low; ERBB2; low; breast cancer; HER2 targeted therapy; trastuzumab; trastuzumab-deruxtecan; T-DXd; SRC-FAMILY KINASES; TRASTUZUMAB DERUXTECAN; ADJUVANT CHEMOTHERAPY; TRANSCRIPTION FACTOR; ACTIVATOR PROTEIN-2; ERBB2; EXPRESSION; GROWTH; GENE; AMPLIFICATION; OVEREXPRESSION;

D O I：

10.2147/BCTT.S366122

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

More than 50% of breast cancers are currently defined as "Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC)", with HER2 immunohistochemistry (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization (FISH) test. In most studies that compared the clinical and biological characteristics of HER2-low BC with HER2-negative BC, HER2-low was not associated with unique clinical and molecular characteristics, and it seems that the importance of HER2 in these tumors is being a docking site for the antibody portion of antibody drug conjugates (ADCs). Current pathological methods may underestimate the proportion of BCs that express low levels of HER2 due to analytical limitations and tumor heterogeneity. In this review we summarize and contextualize the most recent literature on HER2-low breast cancers, including clinical and translational studies We also review the challenges of assessing low HER2 expression in BC and discuss the current and future therapeutic landscape for these tumors.

引用

页码：605 / 616

页数：12

共 118 条

[1] HER2-Low Breast Cancer: Molecular Characteristics and Prognosis [J].

Agostinetto, Elisa ;

Rediti, Mattia ;

Fimereli, Danai ;

Debien, Veronique ;

Piccart, Martine ;

Aftimos, Philippe ;

Sotiriou, Christos ;

de Azambuja, Evandro .

CANCERS, 2021, 13 (11)

[2] Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations Time for a New Look at How to Report Heterogeneity [J].

Allison, Kimberly H. ;

Dintzis, Suzanne M. ;

Schmidt, Rodney A. .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011, 136 (06) :864-871

[3] Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer [J].

Almstedt, Katrin ;

Heimes, Anne-Sophie ;

Kappenberg, Franziska ;

Battista, Marco J. ;

Lehr, Hans-Anton ;

Krajnak, Slavomir ;

Lebrecht, Antje ;

Gehrmann, Mathias ;

Stewen, Kathrin ;

Brenner, Walburgis ;

Weikel, Wolfgang ;

Rahnenfuehrer, Joerg ;

Hengstler, Jan G. ;

Hasenburg, Annette ;

Schmidt, Marcus .

EUROPEAN JOURNAL OF CANCER, 2022, 173 :10-19

[4]

Alroy I, 2000, Breast Dis, V11, P31

[5]

Andre F, 2022, J CLIN ONCOL, V40

[6]

annalsofoncology, 260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial-Annals of Oncology

[7]

Ballinger CA, 1999, MOL CELL BIOL, V19, P4535

[8] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study [J].

Banerji, Udai ;

van Herpen, Carla M. L. ;

Saura, Cristina ;

Thistiethwaite, Fiona ;

Lord, Simon ;

Moreno, Victor ;

Macpherson, Iain R. ;

Boni, Valentina ;

Rolfo, Christian ;

de Vries, Elisabeth G. E. ;

Rottey, Sylvie ;

Geenen, Jilt ;

Eskens, Ferry ;

Gil-Martin, Marta ;

Mommers, Ellen C. ;

Koper, Norbert P. ;

Aftimos, Philippe .

LANCET ONCOLOGY, 2019, 20 (08) :1124-1135

[9] Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer [J].

Bardia, A. ;

Tolaney, S. M. ;

Punie, K. ;

Loirat, D. ;

Oliveira, M. ;

Kalinsky, K. ;

Zelnak, A. ;

Aftimos, P. ;

Dalenc, F. ;

Sardesai, S. ;

Hamilton, E. ;

Sharma, P. ;

Recalde, S. ;

Gil, E. C. ;

Traina, T. ;

O'Shaughnessy, J. ;

Cortes, J. ;

Tsai, M. ;

Vahdat, L. ;

Dieras, V ;

Carey, L. A. ;

Rugo, H. S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. ;

Itri, L. M. ;

Hurvitz, S. A. .

ANNALS OF ONCOLOGY, 2021, 32 (09) :1148-1156

[10] Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities [J].

Beerli, RR ;

Hynes, NE .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) :6071-6076

← 1 2 3 4 5 6 7 8 9 10 →